Bank of America’s Day One Biopharmaceuticals DAWN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q3
Sell
-30,200
Closed -$416K 8210
2024
Q2
$416K Sell
30,200
-2,200
-7% -$32.2K ﹤0.01% 5456
2024
Q1
$535K Buy
+32,400
New +$485K ﹤0.01% 5313
2023
Q3
Sell
-24,500
Closed -$293K 7795
2023
Q2
$293K Buy
+24,500
New +$320K ﹤0.01% 5598

Other funds holding DAWN

Bank of America's DAWN Position: Q1 2026 in Review

Bank of America increased its Day One Biopharmaceuticals (DAWN) stake by 76% in Q1 2026, buying an estimated $11.5M and bringing the position to 1,902,868 shares worth $40.8M. The position accounts for ﹤0.01% of the portfolio, ranked #1748.

Bank of America first reported a position in DAWN in Q2 2021 and has held it in 20 quarters since. 207 funds tracked by Wall St. Rank hold DAWN as of Q1 2026.

  • Bank of America held 1,902,868 shares of Day One Biopharmaceuticals worth $40.8M as of Q1 2026.
  • Bank of America bought 819,050 Day One Biopharmaceuticals shares in Q1 2026, an estimated $11.5M.
  • Day One Biopharmaceuticals made up ﹤0.01% of Bank of America's portfolio in Q1 2026, its #1748 holding.
  • Bank of America first reported a position in Day One Biopharmaceuticals in Q2 2021 and has held it in 20 quarters since.
  • 207 funds tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.